Epigenetics in cancer therapy and nanomedicine

The emergence of nanotechnology applied to medicine has revolutionized the treatment of human cancer. As in the case of classic drugs for the treatment of cancer, epigenetic drugs have evolved in terms of their specificity and efficiency, especially because of the possibility of using more effective...

Full description

Saved in:
Bibliographic Details
Published in:Clinical epigenetics 2019-05, Vol.11 (1), p.81-18, Article 81
Main Authors: Roberti, Annalisa, Valdes, Adolfo F, Torrecillas, Ramón, Fraga, Mario F, Fernandez, Agustin F
Format: Article
Language:English
Subjects:
Analysis
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biological markers
Biomarkers, Tumor
Biomedical materials
Breast cancer
Cancer
Cancer therapies
Cancer treatment
Carbon
Chromosomes
Clinical Trials as Topic
Deoxyribonucleic acid
DNA
DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors
DNA methylation
DNA repair
DNMT inhibitors
Drug Delivery Systems
Enzymes
Epigenesis, Genetic - drug effects
Epigenetic inheritance
Epigenetics
Gene expression
Genetic engineering
Genomes
HDCA inhibitors
Histone Deacetylase Inhibitors - pharmacology
Histone Deacetylase Inhibitors - therapeutic use
Humans
Kinases
Nanocarriers
Nanomedicine
Nanoparticles
Nanotechnology
Neoplasms - drug therapy
Neoplasms - genetics
Oncology
Phosphorylation
Physiology
Precision Medicine
Review
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The emergence of nanotechnology applied to medicine has revolutionized the treatment of human cancer. As in the case of classic drugs for the treatment of cancer, epigenetic drugs have evolved in terms of their specificity and efficiency, especially because of the possibility of using more effective transport and delivery systems. The use of nanoparticles (NPs) in oncology management offers promising advantages in terms of the efficacy of cancer treatments, but it is still unclear how these NPs may be affecting the epigenome such that safe routine use is ensured. In this work, we summarize the importance of the epigenetic alterations identified in human cancer, which have led to the appearance of biomarkers or epigenetic drugs in precision medicine, and we describe the transport and release systems of the epigenetic drugs that have been developed to date.
ISSN:1868-7075
1868-7083
1868-7083
1868-7075
DOI:10.1186/s13148-019-0675-4